The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.

Gynecologic Oncology（2019）

引用 22|浏览96

暂无评分

摘要

•Cervical cancer cells often express the epidermal growth factor receptor (EGFR).•However, the addition of cetuximab to chemotherapy did not produce benefit for advanced/recurrent cervical cancer patients.•The presence of PIK3CA mutations may be associated with resistance to cetuximab treatment.

查看译文

关键词

Cervical cancer,Cetuximab,Randomized phase 2,PIK3CA mutation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要